AI assistant
Sending…
Immuneering Corp — Director's Dealing 2025
Oct 2, 2025
32973_dirs_2025-10-02_d6f4a645-6831-41b3-8a5d-6d83343cbaaf.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2025-10-01
Reporting Person: Bookman Michael (CHIEF LEGAL OFFICER, SECRETARY)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-10-01 | Class A Common Stock | P | 1020 | $6.8299 | Acquired | 4870 | Direct |
More from Immuneering Corp
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 15
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 5
Major Shareholding Notification
2026
Jan 22